{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:28:20Z","timestamp":1793647700426,"version":"4.5.1"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117034","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:31:18Z","timestamp":1731047478000},"page":"117034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance"],"prefix":"10.1016","volume":"281","author":[{"given":"Ebna Azizal","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-783X","authenticated-orcid":false,"given":"Rajesh","family":"R.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pronoy Kanti","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-5757","authenticated-orcid":false,"given":"Rohit","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurubasavaraja Swamy","family":"Purawarga Matada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalmohan","family":"Maji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejmech.2024.117034_bib1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2174\/0929867327666200312112412","article-title":"Recent advances in the design and development of anticancer molecules based on PROTAC technology","volume":"28","author":"Mukhamejanova","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2024.117034_bib2","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.2174\/0929867327666201117141611","article-title":"Recent advances in small molecule PROTACs for the treatment of cancer","volume":"28","author":"Li","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming cancer drug resistance utilizing PROTAC technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117034_bib5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/biom12091257","article-title":"Recent advances of degradation technologies based on PROTAC mechanism","volume":"12","author":"Xiao","year":"2022","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/vaccines11020270","article-title":"Recent advances in PROTAC-based antiviral strategies","volume":"11","author":"Ahmad","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ejmech.2024.117034_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.117034_bib8","article-title":"Recent advances in PROTAC technology toward new therapeutic modalities","volume":"19","author":"Yokoo","year":"2022","journal-title":"Chem. Biodivers."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117034_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.mencom.2022.07.001","article-title":"Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)","volume":"32","author":"Bakulina","year":"2022","journal-title":"Mendeleev Commun."},{"key":"10.1016\/j.ejmech.2024.117034_bib10","article-title":"Application and challenges of nitrogen heterocycles in PROTAC linker","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115246","article-title":"From PROTAC to inhibitor: structure-guided discovery of potent and orally bioavailable BET inhibitors","volume":"251","author":"Koravovic","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib12","series-title":"Cancer 2021: New Therapeutic Approaches for the Treatment of Cancer\u2014Building on Advances in Cancer Biology and the Molecular Genetics of Cancer","first-page":"341","author":"Ruggeri","year":"2021"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-022-01707-5","article-title":"PROTAC\u2019ing oncoproteins: targeted protein degradation for cancer therapy","volume":"22","author":"Kelm","year":"2023","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.ejmech.2024.117034_bib14","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/biomedicines10092100","article-title":"Targeted protein degradation to overcome resistance in cancer therapies: PROTAC and N-degron pathway","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.ejmech.2024.117034_bib15","article-title":"Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy","volume":"3","author":"Han","year":"2022","journal-title":"Cell Rep. Phys. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.ejmech.2024.117034_bib17","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2174\/0113894501273969231102095615","article-title":"N-heterocycle based degraders (Protacs) manifesting anticancer efficacy: recent advances","volume":"24","author":"Banerjee","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2024.117034_bib18","article-title":"Targeting Focal adhesion kinase (FAK) in cancer therapy: a recent update on inhibitors and PROTAC degraders","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"26","key":"10.1016\/j.ejmech.2024.117034_bib19","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.ejmech.2024.117034_bib20","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/app12199674","article-title":"Light-activating PROTACs in cancer: chemical design, challenges, and applications","volume":"12","author":"Negi","year":"2022","journal-title":"Appl. Sci."},{"key":"10.1016\/j.ejmech.2024.117034_bib21","article-title":"Progress in the controllability technology of PROTAC","author":"He","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2024.117034_bib22","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1021\/acs.jmedchem.2c00302","article-title":"Enriching proteolysis targeting chimeras with a second modality: when two are better than one","volume":"65","author":"Salerno","year":"2022","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117034_bib23","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/acs.jmedchem.2c00316","article-title":"Beyond proteolysis-targeting chimeric molecules: designing heterobifunctional molecules based on functional effectors","volume":"65","author":"Hua","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib24","unstructured":"Steinebach C, Ng YLD, Bricelj A, Sosi\u010d I, Kr\u00f6nke J, G\u00fctschow M. PROTAC-MEDIATED INACTIVATION OF E3 LIGASES: FROM TOOLS TO CANCER TREATMENT. Book of.vol. 290."},{"issue":"16","key":"10.1016\/j.ejmech.2024.117034_bib25","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117034_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/13543776.2019.1582645","article-title":"A therapeutic patent overview of MDM2\/X-targeted therapies (2014\u20132018)","volume":"29","author":"Skalniak","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"issue":"18","key":"10.1016\/j.ejmech.2024.117034_bib28","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1021\/acs.jmedchem.3c01264","article-title":"Discovery of ARD-1676 as a highly potent and orally efficacious AR PROTAC degrader with a broad activity against AR mutants for the treatment of AR+ human prostate cancer","volume":"66","author":"Xiang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/molecules26030672","article-title":"Protacs and building blocks: the 2d chemical space in very early drug discovery","volume":"26","author":"Ermondi","year":"2021","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.ejmech.2024.117034_bib30","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.3390\/molecules28104014","article-title":"PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies","volume":"28","author":"Sincere","year":"2023","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.ejmech.2024.117034_bib31","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent advances in pro-PROTAC development to address on-target off-tumor toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib32","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2024.117034_bib33","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"22","key":"10.1016\/j.ejmech.2024.117034_bib34","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2024.117034_bib35","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/ijms22042124","article-title":"An overview of next-generation androgen receptor-targeted therapeutics in development for the treatment of prostate cancer","volume":"22","author":"Mohler","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117034_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The state of the art of PROTAC technologies for drug discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.15212\/AMM-2022-0041","article-title":"Computational strategies for PROTAC drug discovery","volume":"2","author":"Wu","year":"2023","journal-title":"Acta Materia Medica"},{"key":"10.1016\/j.ejmech.2024.117034_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.117034_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"issue":"11","key":"10.1016\/j.ejmech.2024.117034_bib42","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cmdc.202100022","article-title":"\u201cGolden Age\u201d for the discovery of new antileishmanial agents: current status of leishmanicidal gold complexes and prospective targets beyond the trypanothione system","volume":"16","author":"Rosa","year":"2021","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3390\/molecules28031217","article-title":"PROTACs in epigenetic cancer therapy: current status and future opportunities","volume":"28","author":"Liu","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.117034_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.805336","article-title":"Options to improve the action of PROTACs in cancer: development of controlled delivery nanoparticles","volume":"9","author":"Juan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117034_bib47","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.117034_bib48","series-title":"Developing a PROTAC to Degrade the Constitutively Active Onco-GPCR in Uveal Melanoma","author":"Rasmussen","year":"2024"},{"key":"10.1016\/j.ejmech.2024.117034_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC technology: from drug development to probe technology for target deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117034_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1368-7646(02)00121-8","article-title":"Cell cycle regulatory E3 ubiquitin ligases as anticancer targets","volume":"5","author":"Pray","year":"2002","journal-title":"Drug Resist. Updates"},{"issue":"9b","key":"10.1016\/j.ejmech.2024.117034_bib51","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1111\/j.1582-4934.2009.00825.x","article-title":"The ubiquitin\u2010proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation","volume":"13","author":"Vlachostergios","year":"2009","journal-title":"J. Cell Mol. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molcel.2009.04.026","article-title":"A role for ubiquitin in selective autophagy","volume":"34","author":"Kirkin","year":"2009","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/embr.201338025","article-title":"Ubiquitin in the immune system","volume":"15","author":"Zinngrebe","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2024.117034_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43556-021-00043-2","article-title":"E3 ubiquitin ligases: styles, structures and functions","volume":"2","author":"Yang","year":"2021","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2015.08.109","article-title":"Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting","volume":"466","author":"Emmerich","year":"2015","journal-title":"Biochemical and biophysical research communications"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/02648725.2013.801232","article-title":"Proteomic identification of protein ubiquitination events","volume":"29","author":"Xu","year":"2013","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.ejmech.2024.117034_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108690","article-title":"Historical perspective and progress on protein ubiquitination at glutamatergic synapses","volume":"196","author":"Mabb","year":"2021","journal-title":"Neuropharmacology"},{"issue":"46","key":"10.1016\/j.ejmech.2024.117034_bib59","doi-asserted-by":"crossref","first-page":"10789","DOI":"10.1039\/C9SC03445E","article-title":"Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M\/C797S","volume":"10","author":"Lategahn","year":"2019","journal-title":"Chem. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-020-00421-2","article-title":"Targeting ubiquitin signaling for cancer immunotherapy","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib61","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117034_bib62","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/biom10040566","article-title":"Old and new concepts in ubiquitin and NEDD8 recognition","volume":"10","author":"Santonico","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","article-title":"Mechanisms of deubiquitinase specificity and regulation","volume":"86","author":"Mevissen","year":"2017","journal-title":"Annu. Rev. Biochem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117034_bib64","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.cclet.2019.09.044","article-title":"2-Oxo-3, 4-dihydropyrimido [4, 5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant","volume":"31","author":"Hu","year":"2020","journal-title":"Chin. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101077","article-title":"Deubiquitinating enzymes (DUBs): regulation, homeostasis, and oxidative stress response","volume":"297","author":"Snyder","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117034_bib66","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1096\/fj.09-136259","article-title":"The family of ubiquitin\u2010conjugating enzymes (E2s): deciding between life and death of proteins","volume":"24","author":"Van Wijk","year":"2010","journal-title":"Faseb. J."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib67","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1878-0261.12853","article-title":"Genome\u2010scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib\u2010resistant lung cancer","volume":"15","author":"Lee","year":"2021","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41594-018-0182-x","article-title":"Nascent-protein ubiquitination is required for heat shock\u2013induced gene downregulation in human cells","volume":"26","author":"Aprile-Garcia","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-018-0281-y","article-title":"Dural effects of oxidative stress on cardiomyogenesis via Gata4 transcription and protein ubiquitination","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117034_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.152026","article-title":"Roles of protein ubiquitination in inflammatory bowel disease","volume":"225","author":"Xiao","year":"2020","journal-title":"Immunobiology"},{"issue":"9","key":"10.1016\/j.ejmech.2024.117034_bib71","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00299-022-02884-9","article-title":"Emerging roles of the ubiquitin\u2013proteasome pathway in enhancing crop yield by optimizing seed agronomic traits","volume":"41","author":"Varshney","year":"2022","journal-title":"Plant Cell Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib72","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1186\/s12967-023-04540-6","article-title":"Spotlights on ubiquitin-specific protease 12 (USP12) in diseases: from multifaceted roles to pathophysiological mechanisms","volume":"21","author":"Niu","year":"2023","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib73","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41418-020-00706-7","article-title":"Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities","volume":"28","author":"Schmidt","year":"2021","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117034_bib74","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrm2690","article-title":"Physiological functions of the HECT family of ubiquitin ligases","volume":"10","author":"Rotin","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib75","doi-asserted-by":"crossref","first-page":"227S","DOI":"10.1093\/jn\/129.1.227S","article-title":"Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease States12","volume":"129","author":"Lecker","year":"1999","journal-title":"J. Nutr."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin\u2013proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117034_bib77","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0076-6879(05)99054-X","article-title":"Chimeric molecules to target proteins for ubiquitination and degradation","volume":"399","author":"Sakamoto","year":"2005","journal-title":"Methods Enzymol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117034_bib78","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1203\/PDR.0b013e3181d35017","article-title":"Protacs for treatment of cancer","volume":"67","author":"Sakamoto","year":"2010","journal-title":"Pediatr. Res."},{"issue":"13_Supplement","key":"10.1016\/j.ejmech.2024.117034_bib79","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/1538-7445.AM2018-5236","article-title":"ARV-110: an androgen receptor PROTAC degrader for prostate cancer","volume":"78","author":"Neklesa","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117034_bib80","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117034_bib81","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1021\/acs.jnatprod.0c00189","article-title":"Aspeterreurone A, a cytotoxic dihydrobenzofuran\u2013phenyl acrylate hybrid from the deep-sea-derived fungus Aspergillus terreus CC-S06-18","volume":"83","author":"Wang","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2024.117034_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114112","article-title":"Targeting androgen receptor degradation with PROTACs from bench to bedside","volume":"158","author":"Jia","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.117034_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.117034_bib84","series-title":"First-in-human Phase I Study of ARV-110, an Androgen Receptor (AR) PROTAC Degrader in Patients (Pts) with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Following Enzalutamide (ENZ) And\/or Abiraterone (ABI)","author":"Petrylak","year":"2020"},{"key":"10.1016\/j.ejmech.2024.117034_bib85","series-title":"Targeted Protein Degradation by Proteolysis Targeting Chimeras: A Revolution in Small Molecule Drug Discovery","first-page":"225","author":"Du","year":"2022"},{"key":"10.1016\/j.ejmech.2024.117034_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105848","article-title":"Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery","volume":"125","author":"Xi","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.117034_bib87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117034_bib88","article-title":"Abstract GS3-03: GS3-03 ARV-471, a PROTAC\u00ae estrogen receptor (ER) degrader in advanced ER-positive\/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1\/2 study","volume":"83","author":"Schott","year":"2023","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.ejmech.2024.117034_bib89","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC\u00ae vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117034_bib90","unstructured":"ClinicalTrials.gov. Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [updated 2024-05-03; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03888612."},{"key":"10.1016\/j.ejmech.2024.117034_bib91","unstructured":"ClinicalTrials.gov. A Phase 1\/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE\u00ae) in Patients With ER+\/HER2- Locally Advanced or Metastatic Breast Cancer (mBC) [updated 2024-05-06; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04072952."},{"key":"10.1016\/j.ejmech.2024.117034_bib92","unstructured":"ClinicalTrials.gov. A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) [updated 2022-10-24; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04772885?tab=history&a=7."},{"key":"10.1016\/j.ejmech.2024.117034_bib93","unstructured":"ClinicalTrials.gov. A Study of NX-2127 in Adults With Relapsed\/Refractory B-cell Malignancies [updated 2023-11-07; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04830137."},{"key":"10.1016\/j.ejmech.2024.117034_bib94","unstructured":"ClinicalTrials.gov. A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer [updated 2024-04-11; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05080842."},{"key":"10.1016\/j.ejmech.2024.117034_bib95","unstructured":"ClinicalTrials.gov. A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer [updated 2024-04-05; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05067140."},{"key":"10.1016\/j.ejmech.2024.117034_bib96","unstructured":"ClinicalTrials.gov. Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer [updated 2024-06-17; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04428788?tab=history&a=8."},{"key":"10.1016\/j.ejmech.2024.117034_bib97","unstructured":"ClinicalTrials.gov. FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors [updated 2024-04-25; cited 2024 13th July]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04965753."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib98.1","unstructured":"ClinicalTrials.gov. A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer 2024 [updated 2024-01-25"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib98.2","unstructured":"cited 2024 06-09-2024]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05673109?term=NCT05673109&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib99.1","unstructured":"ClinicalTrials.gov. A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients 2024 [updated 2024-03-20"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib99.2","unstructured":"cited 2024 06-09-2024]. Available from: https:\/\/clinicaltrials.gov\/search?cond=Anti Tumor%20Activity%20of%20Oral%20HP518%20in%20mCRPC%20Patients&intr=HP518%20in%20mCRPC%20Patients."},{"key":"10.1016\/j.ejmech.2024.117034_bib100","unstructured":"ClinicalTrials.gov. To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects 2024 [updated 2024-07-24; cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/search?term=NCT06468579."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib101.1","unstructured":"ClinicalTrials.gov. A Study of AC682 In Chinese Patients With ER+\/HER2- Locally Advanced or Metastatic Breast Cancer 2024 [updated 2024-01-25"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib101.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05489679?term=NCT05489679&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib102.1","unstructured":"ClinicalTrials.gov. Safety, PK\/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL 2024 [updated 2023-11-21"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib102.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05233033?term=NCT05233033&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib103.1","unstructured":"ClinicalTrials.gov. A Study of NX-5948 in Adults With Relapsed\/Refractory B-cell Malignancies 2024 [updated 2024-07-11"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib103.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05131022?term=NCT05131022&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib104.1","unstructured":"ClinicalTrials.gov. A Study of AC676 for the Treatment of Relapsed\/Refractory B-Cell Malignancies 2024 [updated 2024-08-06"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib104.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05780034?term=NCT05780034&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib105.1","unstructured":"ClinicalTrials.gov. Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader 2024 [updated 2024-07-18"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib105.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05294731?term=NCT05294731&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib106.1","unstructured":"ClinicalTrials.gov. A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies 2024 [updated 2024-08-19"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib106.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05006716?term=NCT05006716&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib107.1","unstructured":"ClinicalTrials.gov. A Study of HSK29116 in Adults With Relapsed\/Refractory B-cell Malignancies 2024 [updated 2022-08-03"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib107.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04861779?term=NCT04861779&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib108.1","unstructured":"ClinicalTrials.gov. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors 2024 [updated 2024-01-19"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib108.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05355753?term=NCT05355753&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib109.1","doi-asserted-by":"crossref","unstructured":"ClinicalTrials.gov. A Study of RNK05047 in Subjects With Advanced Solid Tumors\/Diffuse Large B-cell Lymphoma (CHAMP-1) 2024 [updated 2023-11-15","DOI":"10.1177\/20363613231193566"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib109.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05487170?term=NCT05487170&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib110.1","unstructured":"ClinicalTrials.gov. Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors 2024 [updated 2023-08-03"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib110.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05225584?term=NCT05225584&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib111.1","unstructured":"ClinicalTrials.gov. A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors 2024 [updated 2024-07-18"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib111.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05668585?term=NCT05668585&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib112.1","unstructured":"ClinicalTrials.gov. Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation 2024 [updated 2023-09-22"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib112.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06050980?term=NCT06050980&rank=1."},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib113.1","unstructured":"ClinicalTrials.gov. A Study of DT2216 in Relapsed\/Refractory Malignancies 2024 [updated 2024-01-18"},{"key":"#cr-split#-10.1016\/j.ejmech.2024.117034_bib113.2","unstructured":"cited 2024 6th sep]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04886622?term=NCT04886622&rank=1."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117034_bib114","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129780","article-title":"Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido [2, 3-d] pyrimidin-7-one-based SOS1 inhibitor","volume":"107","author":"Wang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"13","key":"10.1016\/j.ejmech.2024.117034_bib116","doi-asserted-by":"crossref","first-page":"11354","DOI":"10.1021\/acs.jmedchem.4c00965","article-title":"Development of degraders of cyclin-dependent kinases 4 and 6 based on rational drug design","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2024.117034_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216290","article-title":"Design, synthesis, and antitumor activity evaluation of proteolysis-targeting chimeras as degraders of extracellular signal-regulated kinases 1\/2","volume":"24","author":"Pan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.117034_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106556","article-title":"Discovery of a miniaturized PROTAC with potent activity and high selectivity","volume":"136","author":"Gong","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117034_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.107924","article-title":"Developing potent BTKC481S PROTACs for ibrutinib-resistant malignant lymphoma","volume":"34","author":"Sun","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2024.117034_bib120","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1021\/acs.jmedchem.2c01970","article-title":"Design, synthesis, and biological evaluation of androgen receptor (AR) antagonist-heat shock protein 90 (Hsp90) inhibitor conjugates for targeted therapy of castration-resistant prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2024.117034_bib121","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1248\/cpb.c22-00576","article-title":"Design, synthesis, and biological evaluation of mTOR-targeting PROTACs based on MLN0128 and pomalidomide","volume":"71","author":"Zhang","year":"2023","journal-title":"Chem. Pharm. Bull."},{"issue":"19","key":"10.1016\/j.ejmech.2024.117034_bib122","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1021\/acs.jmedchem.3c00864","article-title":"Design, synthesis, and biological evaluation of proteolysis-targeting chimeras as highly selective and efficient degraders of extracellular signal-regulated kinase 5","volume":"66","author":"Pan","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117867","article-title":"Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1\/PD-L1 interaction","volume":"111","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106762","article-title":"Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma","volume":"140","author":"Xie","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115774","article-title":"Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy","volume":"260","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib126","first-page":"1","article-title":"An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review","author":"Dhiwar","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"10.1016\/j.ejmech.2024.117034_bib127","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/cancers15030611","article-title":"Synthesis and biological activity of a VHL-based PROTAC specific for p38\u03b1","volume":"15","author":"Cubillos-Rojas","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117034_bib128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14756366.2022.2135510","article-title":"Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug","volume":"38","author":"Lee","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107016","article-title":"Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling","volume":"143","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115690","article-title":"Discovery of X10g as a selective PROTAC degrader of Hsp90\u03b1 protein for treating breast cancer","volume":"260","author":"Jiang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117034_bib131","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/molecules28093912","article-title":"Synthesis and antineoplastic activity of a dimer, spiroindolinone pyrrolidinecarboxamide","volume":"28","author":"Cui","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.117034_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117134","article-title":"Design, synthesis, and biological evaluation of BRD4 degraders","volume":"78","author":"Ding","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117293","article-title":"Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands","volume":"86","author":"Xu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117153","article-title":"Design, synthesis and biological evaluation of KRASG12C-PROTACs","volume":"78","author":"Zhang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117237","article-title":"Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands","volume":"82","author":"Cheng","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib136","unstructured":"Jiang M, Wang Y, Zhuang Y, Wang X, Yao L. Design, Synthesis and in Vitro Antitumor Evaluation of EGFR-Targeting Small Molecule Degraders. Vitro Antitumor Evaluation of EGFR-Targeting Small Molecule Degraders."},{"key":"10.1016\/j.ejmech.2024.117034_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116972","article-title":"CDK9 targeting PROTAC L055 inhibits ER\u03b1-positive breast cancer","volume":"177","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117034_bib138","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1021\/acs.jmedchem.2c01665","article-title":"Discovery of a potent and selective STAT5 PROTAC degrader with strong antitumor activity in vivo in acute myeloid leukemia","volume":"66","author":"Kaneshige","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107078","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer","volume":"143","author":"Xiao","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.117034_bib140","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1021\/acs.jmedchem.3c00405","article-title":"Discovery of ARD-2051 as a potent and orally efficacious proteolysis targeting chimera (PROTAC) degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"66","author":"Han","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116167","article-title":"Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase","volume":"267","author":"Alfayomy","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2024.117034_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.107923","article-title":"Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: design, synthesis, and biological evaluations","volume":"34","author":"Chen","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.117034_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107309","article-title":"The design, synthesis and bioactivity evaluation of novel androgen receptor degraders based on hydrophobic tagging","volume":"146","author":"Sun","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.117034_bib144","doi-asserted-by":"crossref","first-page":"11326","DOI":"10.1021\/acs.jmedchem.4c00883","article-title":"Discovery of a highly potent and selective BRD9 PROTAC degrader based on E3 binder investigation for the treatment of hematological tumors","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106327","article-title":"Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer","volume":"131","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106439","article-title":"Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors","volume":"134","author":"Si","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117352","article-title":"Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4","volume":"90","author":"Cai","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117034_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106495","article-title":"Rational design, synthesis and biological evaluation of benzo [d] isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer","volume":"135","author":"Li","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117034_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.107762","article-title":"Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma","volume":"34","author":"Liu","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"15","key":"10.1016\/j.ejmech.2024.117034_bib150","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1021\/acs.jmedchem.3c00953","article-title":"Discovery of SMD-3040 as a potent and selective SMARCA2 PROTAC degrader with strong in vivo antitumor activity","volume":"66","author":"Yang","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T08:58:18Z","timestamp":1734253098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424009164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":165,"alternative-id":["S0223523424009164"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117034","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117034"}}